Seeking Alpha

Goldman raises its price target on Regeneron Pharmaceuticals (REGN +3%) to $240 from $230 after...

Goldman raises its price target on Regeneron Pharmaceuticals (REGN +3%) to $240 from $230 after a survey of 41 U.S.-based cardiologists/lipidologists shows awareness of anti-PCSK9 drugs is widespread and "physicians project to use this class of drugs in 25-50% of their patients one year after approval." Putting it all together, Goldman hikes its peak sales estimates for REGN727 (developed with Sanofi SNY) to $3.5B from $3B and says it expects the company to report Phase III data in Q3. (Previoulsly: GS reiterates Buy on REGN)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|